研究单位：[1]Sun Yat-sen University[2]Fifth Affiliated Hospital, Sun Yat-Sen University[3]Gansu Cancer Hospital[4]Fifth Affiliated Hospital of Guangzhou Medical University[5]Beijing Tongren Hospital[6]Tongji Medical College of Huazhong University of Science & Technology[7]Wuhan Union Hospital, China[8]Shenzhen People's Hospital[9]Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University,Guangzhou,Guangdong,China,51000
研究目的：
This is a prospective, single-arm, multicenter, phase II clinical trial to evaluate the efficacy and safety of Zanubrutinib in combination with Rituximab as a first-line treatment for patients with mucosa-associated lymphoid tissue (MALT) extranodal marginal zone lymphoma.
